Group: Randox
Catalog excerpts
EDUCATIONAL GUIDE ISO 15189:2012 Accreditation Guide QUALITY CONTROL
Open the catalog to page 1ISO 15189:2012 Accreditation Guide Approximately 70% of clinical decisions are based on laboratory test results. Poor laboratory quality can result in unreliable test results ultimately leading to misdiagnosis, inappropriate treatment and may even impact the overall quality of life for the patient. The importance of quality medical services is recognised globally with several bodies existing internationally including ISO (International Organisation for Standardisation) who have developed a set of guidelines and quality systems to ensure reliable test results - ISO 15189:2012. This guide...
Open the catalog to page 21. First vs. Third Party Controls Quality Control products that have been developed and manufactured by the instrument/reagent manufacturer are considered First Party Controls and as such they are referred to as instrument dependent controls. These controls have generally been optimised for use with the manufacturers test system. Whilst this may appear to be beneficial using such First Party Controls will often mask a multitude of weaknesses and consequently are believed to lead to perceived accuracy and a biased assessment of performance. Therefore we can conclude that employing First...
Open the catalog to page 33. Clinically Relevant Levels In addition to features such as third party and commutability, you should also consider whether the quality controls you are using contain analytes at clinically relevant levels. Karkalousos and Evangelopoulos (2011) define clinically relevant levels as levels which are used to “check the performance of laboratory methods across the measuring range”. For example, when measuring Troponin T the cut off value is 14 ng/l. Any patients who present to the hospital with a concentration higher than 14 ng/l in their blood is said to have had a cardiac event. Test...
Open the catalog to page 45. EQA (External Quality Assessment) Peer groups are also a key feature of EQA/PT schemes. These schemes will enable you to objectively review the quality of the results the laboratory produces and demonstrate competency in medical diagnostics. EQA/PT, when implemented correctly, exposes unexpected areas of underperformance, allowing you to identify any potential sources of error. The results measured are then compared against peers from other laboratories on regional, national or international levels. ISO 15189:2012 recommends that, as with IQC, EQA/PT schemes “should provide clinically...
Open the catalog to page 5ACUSERA True third party quality controls As a world leading manufacturer of multi-analyte true third party controls, thousands of laboratories rely on Randox to accurately assess test system performance and ultimately empower them with the confidence required to release patient test results. With more than 390 analytes available, the number of individual controls required to cover your test menu is significantly reduced while simultaneously reducing costs, time and storage space. A choice of formats is available, including liquid or lyophilised, which ensures flexibility and suitability...
Open the catalog to page 6ACUSERA 24•7 Interlaboratory Data Management Designed for use with the Acusera range of third party controls, the Acusera 24•7 software helps laboratories monitor and interpret their QC data. Access to an impressive range of features, including interactive charts, the automatic calculation of Measurement Uncertainty & Sigma Metrics and live peer group data generated from our extensive database of laboratory participants, ensures Acusera 24•7 is the most comprehensive package available. • Advanced statistical analysis with automatic calculation of performance metrics including; Sigma, UM, TE...
Open the catalog to page 7Copyright © 2019 Randox Laboratories Ltd. All rights Reserved. VAT number: GB 151682708. Product availability may vary from country to country. Some products may be for Research Use Only. For more information on product application and availability, please contact your local Randox Representative.
Open the catalog to page 8All Randox Laboratories catalogs and technical brochures
-
Acusera New Controls
8 Pages
-
Acusera 24.7
24 Pages
-
Acusera Third Party Controls
108 Pages
-
Acusera SMART Controls
12 Pages
-
Company Overview
40 Pages
-
LT735 Vivalytic Overview
32 Pages
-
Reagents Brochure
64 Pages
-
sdLDL-C
8 Pages
-
RX SERIES ANALYSER OVERVIEW
24 Pages
-
RX modena
20 Pages
-
RX misano
20 Pages
-
RX Daytona Plus
20 Pages
-
Rx Imola
20 Pages
-
RX Monaco
20 Pages
-
2024 Product List
64 Pages
-
LT107 Evidence Investigator
32 Pages
-
VeraSTAT-V
16 Pages
-
LT033 RIQAS Explained
64 Pages
-
VERASTAT
16 Pages
-
Endocrine Array
4 Pages
-
Cerebral Arrays
4 Pages
-
Thyroid Arrays
4 Pages
-
Respiratory Multiplex Array
8 Pages
-
LT253 Molecular Diagnostics
20 Pages
-
LT367 FH Array Brochure
4 Pages
-
The role of EQA in QC
8 Pages
-
Basic QC Stastics
8 Pages
-
Commutability Guide
4 Pages
-
How to measure uncertainty
8 Pages
-
Troubleshooting QC Errors
8 Pages
-
Qnostics
52 Pages
-
Adiponectin LT519
28 Pages
-
Specific Proteins
40 Pages
-
Linearity sets
12 Pages
-
Antioxidants
16 Pages
-
Cardiology & Lipid Testing
28 Pages
-
Diabetes Portfolio
28 Pages
-
Total Bile Acids
4 Pages
-
VIVALYTIC
30 Pages
-
RANDOX DISCOVERY
36 Pages
-
HbA1c
2 Pages
-
Preparing QC
1 Pages
-
Point of Care Testing
12 Pages
-
LT394 Using QC Multirules
1 Pages
-
Guide to running QC
1 Pages
-
Tumour Marker Arrays
4 Pages
-
Which QC is the Right QC
8 Pages
-
How often is right for QC
6 Pages
-
Cardiac Risk Multiplex Array
4 Pages
-
LT241 Metabolic Array MAY15
8 Pages
-
KRAS / BRAF / PIK3CA Array*
4 Pages
-
Custom Arrays for Biochip
12 Pages
-
LT169 Cardiac Array
4 Pages
Archived catalogs
-
ACUSERA
108 Pages
-
Evidence Evolution
28 Pages
-
Evidence
16 Pages
-
Metabolic Syndrome Arrays
8 Pages
-
STI Multiplex Array
8 Pages
-
Molecular Testing
16 Pages
-
Evidence Investigator
20 Pages
-
Fertility Array
4 Pages
-
Rx Daytona
16 Pages
-
Evidence Investigator
16 Pages
-
Evidence
16 Pages